A non-hormonal method to keep semen gelled so sperm can't reach the egg
Disruption of semen liquefaction using specific KLK3 inhibitors as a new contraceptive
['FUNDING_R01'] · UNIVERSITY OF MISSOURI-COLUMBIA · NIH-11258979
A non-hormonal vaginal drug that keeps semen from thinning so sperm can't swim to the egg, for people who want on-demand contraception.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF MISSOURI-COLUMBIA (nih funded) |
| Locations | 1 site (COLUMBIA, UNITED STATES) |
| Trial ID | NIH-11258979 on ClinicalTrials.gov |
What this research studies
Researchers are developing small drug molecules that block a prostate enzyme (KLK3) so semen stays gel-like after sex and sperm cannot travel to the egg. The team built on prior results showing a similar inhibitor prevented pregnancy in mice and will now optimize compounds and test them in lab and tissue models. Work includes lab experiments, 3D tissue cultures, and preclinical safety steps to prepare for future human testing. The long-term aim is an over-the-counter, reversible option women can use when they want short-term protection.
Who could benefit from this research
Good fit: People who want a short-term, non-hormonal contraceptive option—including women and adolescents seeking over-the-counter contraception—would be the ideal candidates for this approach.
Not a fit: Those seeking long-acting contraception, people actively trying to conceive, men, or anyone with allergies to the drug components would not benefit from this product.
Why it matters
Potential benefit: If successful, this could offer a new non-hormonal, on-demand contraceptive option that is reversible and may reduce unintended teen and overall pregnancies.
How similar studies have performed: Related inhibitors prevented pregnancy in female mice, but applying this approach to humans is novel and has not yet been tested in people.
Where this research is happening
COLUMBIA, UNITED STATES
- UNIVERSITY OF MISSOURI-COLUMBIA — COLUMBIA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WINUTHAYANON, WIPAWEE — UNIVERSITY OF MISSOURI-COLUMBIA
- Study coordinator: WINUTHAYANON, WIPAWEE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.